MedTrace Logo

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

NCT00417716 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2024-06-03

No results posted yet for this study

Summary

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

Conditions

Interventions

DRUG

Intravitreal Bevacizumab

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Adriana Solís-Vivanco, MD · Asociación para Evitar la Ceguera en México

  • Jans Fromow-Guerra, MD PhD · Asociación para Evitar la Ceguera en México

  • Elizabeth Reyna-Castelán · Asociación para Evitar la Ceguera en México

  • Juan M Jiménez-Sierra, MD · Asociación para Evitar la Ceguera en México

  • Myriam Hernández-Rojas, MD · Asociación para Evitar la Ceguera en México

  • Griselda Alvarez-Rivera, MD · Asociación para Evitar la Ceguera en México

  • Hugo Quiroz-Mercado, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2005-09-30
Completion
2006-05-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417716 on ClinicalTrials.gov